Navigation Links
Appeal of Lawsuit by Former Officer Dismissed; Request for Sanctions Granted
Date:2/24/2010

ORLANDO, Fla., Feb. 24 /PRNewswire-FirstCall/ -- GeneLink, Inc. (OTC Bulletin Board: GNLK), a leading consumer genomics biotech company, is pleased to report that the Superior Court of Pennsylvania has dismissed the appeal filed by the Company's former CEO and President, John DePhillipo, and his wife against the Company, its subsidiary GeneWize Life Sciences, Inc., and several of the Company's officers, directors and advisors.  The Court also awarded sanctions in favor of the GeneLink Parties against the DePhillipos and their counsel, with the amount of such sanctions to be determined in the future by the Court of Common Pleas of Pennsylvania, Philadelphia County.  

The DePhillipos' appeal arose from the May 5, 2009 Order and Opinion of the Court of Common Pleas of Pennsylvania, Philadelphia County wherein that Court dismissed the DePhillipos' claims as unviable.  

About GeneLink BioSciences, Inc.:

GeneLink Biosciences is a genomics, biotechnology, and wellness company engaged in genetic profile development, product development, business development and support services for its subsidiaries and distribution partners.  GeneLink's patented and patent pending technologies include proprietary genetic assessments and products linked to personalized health, beauty and wellness applications. For additional information, please visit www.genelinkbio.com.  

About GeneWize Life Sciences, Inc.:

GeneWize is a wholly owned subsidiary of GeneLink Biosciences and is the first network sales company to focus on providing individually customized nutritional and skin care formulations based on a consumer's personal DNA assessment.  The company's mission is to empower individuals to take personal responsibility and control of their health.  For additional information, please visit: www.genewize.com.

This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE GeneLink, Inc.

Back to top

RELATED LINKS
http://www.genelinkbio.com

'/>"/>

SOURCE GeneLink, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
2. XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Insmed to Appeal Delisting Notification From Nasdaq
5. Wyeth To Appeal Arkansas Hormone Therapy Trial Verdicts
6. WorldHeart Announces Delisting Appeal Received and Will be Considered at Hearing July 10, 2008
7. Ortho-McNeil Neurologics to Appeal Patent Ruling on RAZADYNE(R)
8. Court of Appeals Overturns 2005 Patent Verdict Against Cordis
9. Federal Circuit Rules in Marteks Favor in Appeal of Patent Infringement Case
10. Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years
11. Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... Scottsdale, AZ (PRWEB) , ... June 27, 2017 ... ... the world’s first brain mirroring wellness product via Kickstarter campaign on June 15th ... backers have already pre-ordered the B2v2, exceeding the original Kickstarter goal by more ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... design for its patented GX-1 yeast production and fermentation process. The efficiencies ... that rely on micro-organism technologies, most notably the ethanol industry wherein individual production ...
(Date:6/26/2017)... ... June 26, 2017 , ... Third Wave Bioactives, LLC announces the addition ... on leading new business development and ensuring quality customer experience. , Brett ... ingredient industry in technical, marketing and sales roles. “Brett’s background working with customers and ...
(Date:6/23/2017)... ... June 23, 2017 , ... Biova, LLC., the leader in ... Biova’s Board of Directors. Dr. Henig will bring a wealth of scientific experience in ... as the Chief Technical and Scientific Officer of four major global companies in the ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
Breaking Biology News(10 mins):